110 related articles for article (PubMed ID: 8862730)
1. Modulation of melphalan cytotoxic activity in human melanoma cell lines.
Supino R; Caserini C; Orlandi L; Zaffaroni N; Silvestrini R; Vaglini M; Zunino F
Anticancer Drugs; 1996 Jul; 7(5):604-12. PubMed ID: 8862730
[TBL] [Abstract][Full Text] [Related]
2. Sensitization to the cytotoxicity of melphalan by ethacrynic acid and hyperthermia in drug-sensitive and multidrug-resistant Chinese hamster ovary cells.
Turcotte S; Averill-Bates DA
Radiat Res; 2001 Sep; 156(3):272-82. PubMed ID: 11500136
[TBL] [Abstract][Full Text] [Related]
3. Cross-resistance and glutathione-S-transferase-pi levels among four human melanoma cell lines selected for alkylating agent resistance.
Wang YY; Teicher BA; Shea TC; Holden SA; Rosbe KW; al-Achi A; Henner WD
Cancer Res; 1989 Nov; 49(22):6185-92. PubMed ID: 2804968
[TBL] [Abstract][Full Text] [Related]
4. Sensitization of human melanoma cells to the cytotoxic effect of melphalan by the glutathione transferase inhibitor ethacrynic acid.
Hansson J; Berhane K; Castro VM; Jungnelius U; Mannervik B; Ringborg U
Cancer Res; 1991 Jan; 51(1):94-8. PubMed ID: 1988111
[TBL] [Abstract][Full Text] [Related]
5. Modulation of melphalan and cisplatin cytotoxicity in human ovarian cancer cells resistant to alkylating drugs.
Gornati D; Zaffaroni N; Villa R; De Marco C; Silvestrini R
Anticancer Drugs; 1997 Jun; 8(5):509-16. PubMed ID: 9215615
[TBL] [Abstract][Full Text] [Related]
6. Modulation of antitumor alkylating agents by novobiocin, topotecan, and lonidamine.
Schwartz GN; Teicher BA; Eder JP; Korbut T; Holden SA; Ara G; Herman TS
Cancer Chemother Pharmacol; 1993; 32(6):455-62. PubMed ID: 8258194
[TBL] [Abstract][Full Text] [Related]
7. Cytotoxic effects of topotecan combined with various anticancer agents in human cancer cell lines.
Kaufmann SH; Peereboom D; Buckwalter CA; Svingen PA; Grochow LB; Donehower RC; Rowinsky EK
J Natl Cancer Inst; 1996 Jun; 88(11):734-41. PubMed ID: 8637027
[TBL] [Abstract][Full Text] [Related]
8. Rapid development of glutathione-S-transferase-dependent drug resistance in vitro and its prevention by ethacrynic acid.
Caffrey PB; Zhu M; Zhang Y; Chinen N; Frenkel GD
Cancer Lett; 1999 Feb; 136(1):47-52. PubMed ID: 10211938
[TBL] [Abstract][Full Text] [Related]
9. Interaction of ionizing radiation with topotecan in two human tumor cell lines.
Marchesini R; Colombo A; Caserini C; Perego P; Supino R; Capranico G; Tronconi M; Zunino F
Int J Cancer; 1996 May; 66(3):342-6. PubMed ID: 8621255
[TBL] [Abstract][Full Text] [Related]
10. Elevated DNA polymerase alpha, DNA polymerase beta, and DNA topoisomerase II in a melphalan-resistant rhabdomyosarcoma xenograft that is cross-resistant to nitrosoureas and topotecan.
Friedman HS; Dolan ME; Kaufmann SH; Colvin OM; Griffith OW; Moschel RC; Schold SC; Bigner DD; Ali-Osman F
Cancer Res; 1994 Jul; 54(13):3487-93. PubMed ID: 8012971
[TBL] [Abstract][Full Text] [Related]
11. Alkylator resistance in human B lymphoid cell lines: (2). Increased levels of topoisomerase II expression and function in a melphalan-resistant B-CLL cell line.
Pu QQ; Bezwoda WR
Anticancer Res; 2000; 20(4):2569-78. PubMed ID: 10953328
[TBL] [Abstract][Full Text] [Related]
12. Role of cellular glutathione and glutathione S-transferase in the expression of alkylating agent cytotoxicity in human breast cancer cells.
Chen G; Waxman DJ
Biochem Pharmacol; 1994 Mar; 47(6):1079-87. PubMed ID: 8147907
[TBL] [Abstract][Full Text] [Related]
13. A study of ethacrynic acid as a potential modifier of melphalan and cisplatin sensitivity in human lung cancer parental and drug-resistant cell lines.
Rhodes T; Twentyman PR
Br J Cancer; 1992 May; 65(5):684-90. PubMed ID: 1316774
[TBL] [Abstract][Full Text] [Related]
14. Effect of melphalan and hyperthermia on cell cycle progression and cyclin B1 expression in human melanoma cells.
Orlandi L; Zaffaroni N; Bearzatto A; Costa A; Supino R; Vaglini M; Silvestrini R
Cell Prolif; 1995 Nov; 28(11):617-30. PubMed ID: 8555374
[TBL] [Abstract][Full Text] [Related]
15. Induction of alkylator (melphalan) resistance in HL60 cells is accompanied by increased levels of topoisomerase II expression and function.
Pu QQ; Bezwoda WR
Mol Pharmacol; 1999 Jul; 56(1):147-53. PubMed ID: 10385695
[TBL] [Abstract][Full Text] [Related]
16. Glutathione depletion induced by c-Myc downregulation triggers apoptosis on treatment with alkylating agents.
Biroccio A; Benassi B; Fiorentino F; Zupi G
Neoplasia; 2004; 6(3):195-206. PubMed ID: 15153331
[TBL] [Abstract][Full Text] [Related]
17. Effect of melphalan and hyperthermia on p34cdc2 kinase activity in human melanoma cells.
Orlandi L; Zaffaroni N; Bearzatto A; Silvestrini R
Br J Cancer; 1996 Dec; 74(12):1924-8. PubMed ID: 8980391
[TBL] [Abstract][Full Text] [Related]
18. Addition of a topoisomerase I inhibitor to trimodality therapy [cis-diamminedichloroplatinum(II)/heat/radiation] in a murine tumor.
Teicher BA; Holden SA; Khandakar V; Herman TS
J Cancer Res Clin Oncol; 1993; 119(11):645-51. PubMed ID: 8394365
[TBL] [Abstract][Full Text] [Related]
19. Sensitivity to topoisomerase I inhibitors and cisplatin is associated with epidermal growth factor receptor expression in human cervical squamous carcinoma ME180 sublines.
Ling YH; Donato NJ; Perez-Soler R
Cancer Chemother Pharmacol; 2001 Jun; 47(6):473-80. PubMed ID: 11459199
[TBL] [Abstract][Full Text] [Related]
20. Schedule-dependent cytotoxicity of topotecan alone and in combination chemotherapy regimens.
Cheng MF; Chatterjee S; Berger NA
Oncol Res; 1994; 6(6):269-79. PubMed ID: 7865902
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
